AM Best Downgrades Credit Ratings of Nationwide Mutual Insurance Company and Its Property/Casualty Subsidiaries; Affirms Credit Ratings of Life Affiliates
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has downgraded the Financial Strength Rating (FSR) to A (Excellent) from A+ (Superior) and the Long-Term Issuer... Read more.
Earphones and Headphones Global Strategic Business Report 2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Earphones and Headphones – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s... Read more.
Chevron Plans $16 Billion in 2024 Capex, Led by U.S. Upstream
SUGAR LAND, Texas–(BUSINESS WIRE)–Researched by Industrial Info Resources — Chevron Corporation (NYSE:CVX) (San Ramon, California) has announced... Read more.
Cincinnati Eye Institute, an EyeCare Partners Practice, Opens New CEI Retina Clinic at The Landings in Blue Ash
Site is Unique in its Size and Full Dedication to Medical and Surgical Treatment of Retinal Diseases CINCINNATI–(BUSINESS WIRE)–EyeCare Partners (ECP),... Read more.
Cboe Canada Continues Support of Critical Minerals Sector with Listing of LiTHOS Energy
TORONTO–(BUSINESS WIRE)–$LITS #Cboe—Cboe Canada, the new business name of the NEO Exchange, is excited to welcome LiTHOS Energy Ltd. (“LiTHOS”),... Read more.
Cherry Hill Mortgage Investment Corporation Announces Common and Preferred Dividends for the Fourth Quarter 2023
FARMINGDALE, N.J.–(BUSINESS WIRE)–Cherry Hill Mortgage Investment Corporation (NYSE: CHMI) today announced that its Board of Directors declared a... Read more.
NextGen Healthcare’s UGM23 Inspires Attendees with Transformative, AI-Driven Physician and Patient Solutions
Excellence in Healthcare Awards Presented to Client Innovators Also a Highlight of 3-Day Event REMOTE-FIRST COMPANY/ORLANDO, Fla.–(BUSINESS WIRE)–#NextGenHealthcare–Thousands... Read more.
NiKang Therapeutics Enters into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma
– Study will evaluate the potential of triple combination of NKT2152, atezolizumab and bevacizumab versus atezolizumab and bevacizumab alone, in first line... Read more.
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023
This new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months)... Read more.
Advisor2X Welcomes Andrew Wexler as Director of Business Development
The seasoned industry veteran will lead the company’s growth effort WILMINGTON, N.C.–(BUSINESS WIRE)–Advisor2X (A2X), delivering online shows and live... Read more.